Novo Nordisk CEO Mike Doustdar Talks Drug Sales
Bloomberg Talks
00:00
Market Reaction to Novo Nordisk's Forecast Cut
Guy Johnson asks whether the recent share-price bounce means Q3 is the low point and Mike Doustdar explains quarterly headwinds and expected negative Q4.
Play episode from 00:23
Transcript
